Aprea Therapeutics Inc (NASDAQ: APRE) has announced results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
In 33 patients enrolled in the trial, the relapse-free survival (RFS) at 1-year post-transplant was 58%, and the median RFS was 12.1 months.
The overall survival (OS) at 1-year post-transplant was 79%, with a median OS of 19.3 months.
The Company compares the results with prior clinical trials evaluating post-transplant outcomes that reported a 1-year post-transplant RFS of ~30% and a median OS of ~5-8 months.
The post-transplant regimen of eprenetapopt and azacitidine was well tolerated.
The Company plans to discuss the data from this Phase 2 clinical trial with the FDA in the second half of 2021.
Price Action: APRE shares are up 6.90% at $5.42 during the premarket session on the last check Wednesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.